Profitability Of Infused Biologics For Hospitals And Physician Practices: Case Study Of Keytruda

Health Affairs · Published 2026-08-01 · DOI 10.1377/hlthaff.2026.00334

Authors (4)

James C. Robinson, Ari Kosorukuv, Mark Thomson, Christopher M. Whaley

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Robinson, J., Kosorukuv, A., Thomson, M., et al. (2026). Profitability Of Infused Biologics For Hospitals And Physician Practices: Case Study Of Keytruda. Health Affairs. https://doi.org/10.1377/hlthaff.2026.00334

Related articles

• The Extent Of Gender/Sex Variables Included In Clinical Algorithms Across Medical Specialties · Health Affairs · 2026 · Same journal
• Participatory Systems Science To Identify Local Adaptation Strategies For Extreme Heat In King County, Washington · Health Affairs · 2026 · Same journal
• Health Insurance As Climate Adaptation: A Practical Framework · Health Affairs · 2026 · Same journal
• The Uneven Distribution Of Patient Portal Messages Across Patients And Physicians · Health Affairs · 2026 · Same journal
• Who Pays When Temperatures Soar? · Health Affairs · 2026 · Same journal
• Errata · Health Affairs · 2026 · Same journal
• Rhode Island’s Affordability Standards Led To Substantial Reductions In Hospital Staffing And Labor Costs By 2022 · Health Affairs · 2026 · Same journal
• Cold-Related Illness In An Era Of Extreme Climate Events: US Trends, 1998–2022 · Health Affairs · 2026 · Same journal
• Health Care Workers In A Storm’s Path · Health Affairs · 2026 · Same journal
• The South Had The Lowest Rates Of Hospice And Palliative Medicine–Certified Providers In The US, 2024 · Health Affairs · 2026 · Same journal